It has been a banner year for biotech buyouts, and these are two of the prime targets.

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.

BioNTech's Q3 revenue rose to €1.244 billion ($1.36 billion), driven by earlier COVID-19 vaccine approvals. Q3 net profit climbed to €198.1 million, with EPS increasing to 81 cents from 66 cents YoY.

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

The COVID-19 pandemic was a rare event. Governments took it upon themselves to inoculate their populations by buying millions of doses of vaccines from companies such as BioNTech and Pfizer. The ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

BioNTech is flush with Covid-19 vaccine revenue and it’s putting some of that money to work by acquiring rights to a therapy in the hot area of antibody drug conjugates, or ADCs. It’s the second such ...

BioNTech had little to say about its pipeline progress on Monday. But it did report COVID vaccine sales which more than doubled analyst consensus. (Photo by Sean Gallup/Getty Images) BioNTech reported ...

HAMBURG, June 11 (Reuters) - BioNTech (22UAy.DE), opens new tab will go to court on Monday to defend itself against a lawsuit from a German woman who is seeking damages for alleged side effects of its ...

BioNTech rolled out an extensive clinical dataset at this year’s ASCO conference, yet its shares continue to trade well below their highs — a disconnect that has frustrated bulls and left the company ...

One major crux of BioNTech’s sales potential this year is the renegotiation of the German biotech’s supply contract with the European Commission. (BioNTech) After garnering worldwide acclaim over the ...